
Zodasiran, a hepatocyte-targeted small interfering RNA, significantly reduces triglycerides, LDL cholesterol, and other lipid markers in patients with mixed hyperlipidemia on stable statin therapy, with a favorable safety profile.


coremsg

The hepatocyte-targeted small interfering RNA lowers triglyceride and other lipoprotein levels, and even reduces liver fat, report trial investigators.

Gene Silencing Benefit of Zodasiran in Hyperlipidemia

zodasiran-effectively-lowers-triglycerides-and-improves-lipid-profile-in-patients-with-mixed-hyperlipidemia-on-statin-therapy


Zodasiran Effectively Lowers Triglycerides and Improves Lipid Profile in Patients with Mixed Hyperlipidemia on Statin Therapy
